Plain-English translation of NCT06194929 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether a combination of medications called and (with or without a third drug called ) can shrink melanoma tumors in the brain. Researchers are particularly interested in patients whose cancer has progressed despite previous immunotherapy treatments. The goal is to see if this new medication combination can work where other treatments have not.
Many people with melanoma that has spread to the brain don't respond well to current treatments, or their tumors stop responding over time. This trial exists to find out whether this new medication combination might offer hope for patients in that situation.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would take oral medications at home on a 3-week-on, 1-week-off schedule in 4-week cycles. Depending on which study group you're in, you might take two or three different medications. You would need regular visits to the clinic for blood tests, imaging scans to check how your brain tumors are responding, and heart function tests. The study is still recruiting participants, so your treatment plan and duration would be discussed with your research team.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States